BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
AFT Leaves X Over AI-Generated Images of Minors 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
ROCKVILLE, Md., March 28, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 12:10 PM ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
